While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.

The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.

The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.

Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.